Fonte: Journal of clinical oncology. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS, QUIMIOTERAPIA ADJUVANTE, INIBIDORES DE ENZIMAS, RECEPTORES DE ESTEROIDES, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIMAWI, Mothaffar et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. Journal of clinical oncology, v. 36, n. 28, p. 2826-2835, 2018Tradução . . Disponível em: https://doi.org/10.1200/JCO.2017.76.7863. Acesso em: 12 set. 2024.APA
Rimawi, M., Ferrero, J. -M., Haba-rodriguez, J. de la, Poole, C., Placido, S. D., Osborne, C. K., et al. (2018). First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. Journal of clinical oncology, 36( 28), 2826-2835. doi:10.1200/JCO.2017.76.7863NLM
Rimawi M, Ferrero J-M, Haba-rodriguez J de la, Poole C, Placido SD, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial [Internet]. Journal of clinical oncology. 2018 ; 36( 28): 2826-2835.[citado 2024 set. 12 ] Available from: https://doi.org/10.1200/JCO.2017.76.7863Vancouver
Rimawi M, Ferrero J-M, Haba-rodriguez J de la, Poole C, Placido SD, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial [Internet]. Journal of clinical oncology. 2018 ; 36( 28): 2826-2835.[citado 2024 set. 12 ] Available from: https://doi.org/10.1200/JCO.2017.76.7863